Immunotherapy for Spondyloarthritis (SpA)

  • Jiao Sun
  • Hiroki HayashiEmail author


Spondyloarthritis (SpA) is an umbrella term for chronic inflammatory conditions that affect the joints and entheses (the region of attachment between ligaments or tendons and bones) at the sacroiliac region and spine, negatively impacting the patient’s daily life. Because human leukocyte antigen (HLA)-B27, a class I surface antigen encoded in the major histocompatibility complex (MHC), was identified as a strong genetic risk factor, several major theories for the pathological mechanisms have been proposed based on in vitro and translational studies. Additionally, emerging lines of evidence over the last decade suggest that the IL-23/IL-17 axis has a critical role (roles) in the pathology of SpA. Recently, molecular immunotherapy using antibodies has been studied and developed as a therapeutic option to treat SpA. This chapter describes antibody-based immunotherapies targeting arthritogenic inflammatory pathways based on proposed HLA-B27-related mechanisms.


HLA-B27 Autoimmune disorder Endoplasmic reticulum (ER) Unfolded protein reaction (UPR) IL-17A IL-23 TNF-α 


  1. Allen RL, O’Callaghan CA, McMichael AJ, Bowness P (1999) Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure. J Immunol 162:5045–5048PubMedPubMedCentralGoogle Scholar
  2. Assier E, Bessis N, Zagury JF, Boissier MC (2017) IL-1 vaccination is suitable for treating inflammatory diseases. Front Pharmacol 8:6PubMedPubMedCentralCrossRefGoogle Scholar
  3. Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewe R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382:1705–1713PubMedCrossRefPubMedCentralGoogle Scholar
  4. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, Group MS, Group MS (2015) Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 373:2534–2548PubMedCrossRefPubMedCentralGoogle Scholar
  5. Barkham N, Kong KO, Tennant A, Fraser A, Hensor E, Keenan AM, Emery P (2005) The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis. Rheumatology (Oxford) 44:1277–1281CrossRefGoogle Scholar
  6. Benjamin R, Parham P (1990) Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol Today 11:137–142PubMedCrossRefPubMedCentralGoogle Scholar
  7. Benjamin RJ, Madrigal JA, Parham P (1991) Peptide binding to empty HLA-B27 molecules of viable human cells. Nature 351:74–77PubMedCrossRefPubMedCentralGoogle Scholar
  8. Bird LA, Peh CA, Kollnberger S, Elliott T, McMichael AJ, Bowness P (2003) Lymphoblastoid cells express HLA-B27 homodimers both intracellularly and at the cell surface following endosomal recycling. Eur J Immunol 33:748–759PubMedCrossRefPubMedCentralGoogle Scholar
  9. Bowness P (2002) HLA B27 in health and disease: a double-edged sword? Rheumatology (Oxford) 41:857–868CrossRefGoogle Scholar
  10. Bowness P, Ridley A, Shaw J, Chan AT, Wong-Baeza I, Fleming M, Cummings F, McMichael A, Kollnberger S (2011) Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol 186:2672–2680PubMedPubMedCentralCrossRefGoogle Scholar
  11. Braun J, Sieper J (2004) Biological therapies in the spondyloarthritides – the current state. Rheumatology 43:1072–1084PubMedCrossRefPubMedCentralGoogle Scholar
  12. Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369:1379–1390PubMedCrossRefPubMedCentralGoogle Scholar
  13. Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, Readie A, Martin R, Mpofu S, Richards HB, Group MS (2017) Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 76:1070–1077PubMedCrossRefPubMedCentralGoogle Scholar
  14. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD (1973) Ankylosing spondylitis and HL-A 27. Lancet 1:904–907PubMedCrossRefPubMedCentralGoogle Scholar
  15. Chan AT, Kollnberger SD, Wedderburn LR, Bowness P (2005) Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum 52:3586–3595PubMedCrossRefPubMedCentralGoogle Scholar
  16. Colbert RA, DeLay ML, Klenk EI, Layh-Schmitt G (2010) From HLA-B27 to spondyloarthritis: a journey through the ER. Immunol Rev 233:181–202PubMedPubMedCentralCrossRefGoogle Scholar
  17. DeLay ML, Turner MJ, Klenk EI, Smith JA, Sowders DP, Colbert RA (2009) HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum 60:2633–2643PubMedPubMedCentralCrossRefGoogle Scholar
  18. Dubash S, McGonagle D, Marzo-Ortega H (2018) New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice. Ther Adv Chronic Dis 9:77–87PubMedCrossRefPubMedCentralGoogle Scholar
  19. Evans DM, Spencer CC, Pointon JJ, Su Z, Harvey D, Kochan G, Oppermann U, Dilthey A, Pirinen M, Stone MA, Appleton L, Moutsianas L, Leslie S, Wordsworth T, Kenna TJ, Karaderi T, Thomas GP, Ward MM, Weisman MH, Farrar C, Bradbury LA, Danoy P, Inman RD, Maksymowych W, Gladman D, Rahman P, Spondyloarthritis Research Consortium of C, Morgan A, Marzo-Ortega H, Bowness P, Gaffney K, Gaston JS, Smith M, Bruges-Armas J, Couto AR, Sorrentino R, Paladini F, Ferreira MA, Xu H, Liu Y, Jiang L, Lopez-Larrea C, Diaz-Pena R, Lopez-Vazquez A, Zayats T, Band G, Bellenguez C, Blackburn H, Blackwell JM, Bramon E, Bumpstead SJ, Casas JP, Corvin A, Craddock N, Deloukas P, Dronov S, Duncanson A, Edkins S, Freeman C, Gillman M, Gray E, Gwilliam R, Hammond N, Hunt SE, Jankowski J, Jayakumar A, Langford C, Liddle J, Markus HS, Mathew CG, OT MC, MI MC, Palmer CN, Peltonen L, Plomin R, Potter SC, Rautanen A, Ravindrarajah R, Ricketts M, Samani N, Sawcer SJ, Strange A, Trembath RC, Viswanathan AC, Waller M, Weston P, Whittaker P, Widaa S, Wood NW, McVean G, Reveille JD, Wordsworth BP, Brown MA, Donnelly P, Australo-Anglo-American Spondyloarthritis C, Wellcome Trust Case Control C (2011) Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 43:761–767PubMedPubMedCentralCrossRefGoogle Scholar
  20. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P, Group U-I-US (2016) Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 375:1946–1960PubMedCrossRefPubMedCentralGoogle Scholar
  21. Gaffen SL, Jain R, Garg AV, Cua DJ (2014) The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 14:585–600PubMedPubMedCentralCrossRefGoogle Scholar
  22. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index. J Rheumatol 21:2286–2291PubMedPubMedCentralGoogle Scholar
  23. Giles J, Shaw J, Piper C, Wong-Baeza I, McHugh K, Ridley A, Li D, Lenart I, Antoniou AN, DiGleria K, Kuroki K, Maenaka K, Bowness P, Kollnberger S (2012) HLA-B27 homodimers and free H chains are stronger ligands for leukocyte Ig-like receptor B2 than classical HLA class I. J Immunol 188:6184–6193PubMedPubMedCentralCrossRefGoogle Scholar
  24. Goodall JC, Wu C, Zhang Y, McNeill L, Ellis L, Saudek V, Gaston JS (2010) Endoplasmic reticulum stress-induced transcription factor, CHOP, is crucial for dendritic cell IL-23 expression. Proc Natl Acad Sci U S A 107:17698–17703PubMedPubMedCentralCrossRefGoogle Scholar
  25. Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL, Group U-S, Group U-S, Group U-S (2016) Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 375:345–356PubMedCrossRefPubMedCentralGoogle Scholar
  26. Gravallese EM, Schett G (2018) Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis. Nat Rev Rheumatol 14:631–640PubMedCrossRefPubMedCentralGoogle Scholar
  27. Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD (1990) Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 63:1099–1112PubMedCrossRefPubMedCentralGoogle Scholar
  28. Haroon N, Kim TH, Inman RD (2012) NSAIDs and radiographic progression in ankylosing spondylitis Bagging big game with small arms? Ann Rheum Dis 71:1593–1595PubMedCrossRefPubMedCentralGoogle Scholar
  29. Hermann E, Yu DT, Meyer zum Buschenfelde KH, Fleischer B (1993) HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 342:646–650PubMedCrossRefPubMedCentralGoogle Scholar
  30. Inman RD (2006) Mechanisms of disease: infection and spondyloarthritis. Nat Clin Pract Rheumatol 2:163–169PubMedCrossRefPubMedCentralGoogle Scholar
  31. International Genetics of Ankylosing Spondylitis C, Cortes A, Hadler J, Pointon JP, Robinson PC, Karaderi T, Leo P, Cremin K, Pryce K, Harris J, Lee S, Joo KB, Shim SC, Weisman M, Ward M, Zhou X, Garchon HJ, Chiocchia G, Nossent J, Lie BA, Forre O, Tuomilehto J, Laiho K, Jiang L, Liu Y, Wu X, Bradbury LA, Elewaut D, Burgos-Vargas R, Stebbings S, Appleton L, Farrah C, Lau J, Kenna TJ, Haroon N, Ferreira MA, Yang J, Mulero J, Fernandez-Sueiro JL, Gonzalez-Gay MA, Lopez-Larrea C, Deloukas P, Donnelly P, Australo-Anglo-American Spondyloarthritis C, Groupe Francaise d’Etude Genetique des S, Nord-Trondelag Health S, Spondyloarthritis Research Consortium of C, Wellcome Trust Case Control C, Bowness P, Gafney K, Gaston H, Gladman DD, Rahman P, Maksymowych WP, Xu H, Crusius JB, van der Horst-Bruinsma IE, Chou CT, Valle-Onate R, Romero-Sanchez C, Hansen IM, Pimentel-Santos FM, Inman RD, Videm V, Martin J, Breban M, Reveille JD, Evans DM, Kim TH, Wordsworth BP, Brown MA (2013) Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet 45:730–738CrossRefGoogle Scholar
  32. Jacques P, McGonagle D (2014) The role of mechanical stress in the pathogenesis of spondyloarthritis and how to combat it. Best Pract Res Clin Rheumatol 28:703–710PubMedCrossRefPubMedCentralGoogle Scholar
  33. Kollnberger S, Bird L, Sun MY, Retiere C, Braud VM, McMichael A, Bowness P (2002) Cell-surface expression and immune receptor recognition of HLA-B27 homodimers. Arthritis Rheum 46:2972–2982PubMedCrossRefPubMedCentralGoogle Scholar
  34. Kollnberger S, Bird LA, Roddis M, Hacquard-Bouder C, Kubagawa H, Bodmer HC, Breban M, McMichael AJ, Bowness P (2004) HLA-B27 heavy chain homodimers are expressed in HLA-B27 transgenic rodent models of spondyloarthritis and are ligands for paired Ig-like receptors. J Immunol 173:1699–1710PubMedCrossRefPubMedCentralGoogle Scholar
  35. Lin P, Bach M, Asquith M, Lee AY, Akileswaran L, Stauffer P, Davin S, Pan Y, Cambronne ED, Dorris M, Debelius JW, Lauber CL, Ackermann G, Baeza YV, Gill T, Knight R, Colbert RA, Taurog JD, Van Gelder RN, Rosenbaum JT (2014) HLA-B27 and human beta2-microglobulin affect the gut microbiota of transgenic rats. PLoS One 9:e105684PubMedPubMedCentralCrossRefGoogle Scholar
  36. Mear JP, Schreiber KL, Munz C, Zhu X, Stevanovic S, Rammensee HG, Rowland-Jones SL, Colbert RA (1999) Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J Immunol 163:6665–6670PubMedPubMedCentralGoogle Scholar
  37. Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD, Group S-PS (2017) Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 76:79–87PubMedCrossRefPubMedCentralGoogle Scholar
  38. Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M, Group S-PS (2017) Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet 389:2317–2327PubMedCrossRefPubMedCentralGoogle Scholar
  39. Powis SJ, Colbert RA (2016) Editorial: HLA-B27: the story continues to unfold. Arthritis Rheumatol 68:1057–1059PubMedPubMedCentralGoogle Scholar
  40. Ramiro S, Landewe R, van Tubergen A, Boonen A, Stolwijk C, Dougados M, van den Bosch F, van der Heijde D (2015) Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. RMD Open 1:e000153PubMedPubMedCentralCrossRefGoogle Scholar
  41. Raychaudhuri SP, Raychaudhuri SK (2016) IL-23/IL-17 axis in spondyloarthritis-bench to bedside. Clin Rheumatol 35:1437–1441PubMedCrossRefPubMedCentralGoogle Scholar
  42. Schlosstein L, Terasaki PI, Bluestone R, Pearson CM (1973) High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 288:704–706PubMedCrossRefPubMedCentralGoogle Scholar
  43. Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, Gorman DM, Bowman EP, McClanahan TK, Yearley JH, Eberl G, Buckley CD, Kastelein RA, Pierce RH, Laface DM, Cua DJ (2012) IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 18:1069–1076PubMedCrossRefPubMedCentralGoogle Scholar
  44. Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M (2014) Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 73:95–100PubMedCrossRefPubMedCentralGoogle Scholar
  45. Sieper J, Braun J, Kay J, Badalamenti S, Radin AR, Jiao L, Fiore S, Momtahen T, Yancopoulos GD, Stahl N, Inman RD (2015) Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis 74:1051–1057PubMedCrossRefPubMedCentralGoogle Scholar
  46. Smith JA, Colbert RA (2014) Review: the interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis Rheumatol 66:231–241PubMedPubMedCentralCrossRefGoogle Scholar
  47. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, Sieper J (2010) Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 62:1290–1297PubMedCrossRefPubMedCentralGoogle Scholar
  48. Turner MJ, Delay ML, Bai S, Klenk E, Colbert RA (2007) HLA-B27 up-regulation causes accumulation of misfolded heavy chains and correlates with the magnitude of the unfolded protein response in transgenic rats: implications for the pathogenesis of spondylarthritis-like disease. Arthritis Rheum 56:215–223PubMedCrossRefPubMedCentralGoogle Scholar
  49. Van Praet L, Van den Bosch FE, Jacques P, Carron P, Jans L, Colman R, Glorieus E, Peeters H, Mielants H, De Vos M, Cuvelier C, Elewaut D (2013) Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 72:414–417PubMedCrossRefPubMedCentralGoogle Scholar
  50. Wendling D (2013) Looking for the best target for biologic treatment of spondyloarthritis. Expert Rev Clin Immunol 9:1005–1007PubMedCrossRefPubMedCentralGoogle Scholar
  51. Wendling D, Toussirot E (2004) Anti-TNF-alpha therapy in ankylosing spondylitis. Expert Opin Pharmacother 5:1497–1507PubMedCrossRefPubMedCentralGoogle Scholar
  52. Wong-Baeza I, Ridley A, Shaw J, Hatano H, Rysnik O, McHugh K, Piper C, Brackenbridge S, Fernandes R, Chan A, Bowness P, Kollnberger S (2013) KIR3DL2 binds to HLA-B27 dimers and free H chains more strongly than other HLA class I and promotes the expansion of T cells in ankylosing spondylitis. J Immunol 190:3216–3224PubMedPubMedCentralCrossRefGoogle Scholar
  53. Zochling J, Smith EU (2010) Seronegative spondyloarthritis. Best Pract Res Clin Rheumatol 24:747–756PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Health Development and Medicine, School of MedicineOsaka UniversitySuita, OsakaJapan

Personalised recommendations